The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.
Immunotherapy
Lung cancer
Neoantigen
Vaccine
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
11
2020
revised:
27
01
2021
accepted:
28
01
2021
pubmed:
14
2
2021
medline:
8
7
2021
entrez:
13
2
2021
Statut:
ppublish
Résumé
All tumors harbor unique mutant peptides, some of which are able to elicit T-cell-mediated immune responses. These are known as neoantigens. Lung cancers bear a heavy mutational burden and hence many potential neoantigens. Neoantigens are increasingly recognized as key mediators of tumor-specific immune activation and have been identified as potential targets for personalized cancer therapies. In this review, we discuss the current data on neoantigens in lung cancer and provide an overview of the recent advances in neoantigen-based immunotherapy. Furthermore, we look ahead to highlight the major opportunities and challenges for the clinical application of neoantigen-based treatment strategies for thoracic and other malignancies.
Identifiants
pubmed: 33581342
pii: S1556-0864(21)01698-1
doi: 10.1016/j.jtho.2021.01.1624
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
922-932Informations de copyright
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.